[Change of toxic and antineoplastic properties of ftorafur by means of action on nonspecific microsomal oxidase]. 1979

G A Belitskiĭ, and V M Bukhman, and I A Konopleva

The inducers of microsomal hydroxylases, phenobarbitone and methylcholanthrene, inhibited the development of neurotoxic shock provoked by high doses of ftorafur in mice, but stimulated the animal mortality on the 4th-8th day after the drug administration. The opposite effect on both toxicity manifestations has been obtained under the action of the inhibitor SKF 525-A. Pretreatment of the animals with phenobarbitone or phenobarbitone-methylcholanthrene combination markedly increased the antineoplastic activity of ftorafur determined by a loss of the spleen weight in mice infected with Rauscher's leukemia.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008748 Methylcholanthrene A carcinogen that is often used in experimental cancer studies. 20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D011335 Proadifen An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity. Propyladiphenin,Diethylaminoethyldiphenylpropyl Acetate,Proadifen Hydrochloride,SK&F-525-A,SK-525A,SKF-525-A,SKF-525A,Acetate, Diethylaminoethyldiphenylpropyl,Hydrochloride, Proadifen,SK 525A,SK&F 525 A,SK&F525A,SK525A,SKF 525 A,SKF525A
D011925 Rauscher Virus A strain of MURINE LEUKEMIA VIRUS associated with mouse tumors similar to those caused by the FRIEND MURINE LEUKEMIA VIRUS. It is a replication-competent murine leukemia virus. It can act as a helper virus when complexing with a defective transforming component, RAUSCHER SPLEEN FOCUS-FORMING VIRUS. Rauscher leukemia virus,Rauscher leukemia viruses,Virus, Rauscher,leukemia viruses, Rauscher
D004336 Drug Antagonism Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy. Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

G A Belitskiĭ, and V M Bukhman, and I A Konopleva
January 1981, Cancer chemotherapy and pharmacology,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
January 1976, Farmakologiia i toksikologiia,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
January 1972, Voprosy meditsinskoi khimii,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
January 1963, Voprosy onkologii,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
January 1967, Farmakologiia i toksikologiia,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
December 1968, The Kumamoto medical journal,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
November 1981, Biulleten' eksperimental'noi biologii i meditsiny,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
October 1971, Die Naturwissenschaften,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
June 1966, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
G A Belitskiĭ, and V M Bukhman, and I A Konopleva
December 1978, Minerva medica,
Copied contents to your clipboard!